These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27760922)

  • 1. [Advances in drug development for hepatitis C].
    Suzuki T; Nakashima K; Chida T; Ito M
    Uirusu; 2015; 65(2):239-244. PubMed ID: 27760922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hepatitis C virus genotype 3-infection.
    Pol S; Vallet-Pichard A; Corouge M
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
    Yau AH; Yoshida EM
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):445-51. PubMed ID: 25229466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era in the treatment of chronic hepatitis C infection.
    Jothimani D; Chandy GM; Conjeevaram H
    Indian J Gastroenterol; 2013 Mar; 32(2):71-9. PubMed ID: 23054947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon free therapy with direct acting antivirals for HCV.
    Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
    El-Shamy A; Nagano-Fujii M; Sasase N; Imoto S; Kim SR; Hotta H
    Hepatology; 2008 Jul; 48(1):38-47. PubMed ID: 18537193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
    Shahid I; Ibrahim MM
    Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.